Forster S, Radpour R, Ochsenbein A
Front Immunol. 2023; 14:1243997.
PMID: 37744361
PMC: 10516567.
DOI: 10.3389/fimmu.2023.1243997.
Krishnan S, Bebawy M
Mol Cancer. 2023; 22(1):79.
PMID: 37120508
PMC: 10148481.
DOI: 10.1186/s12943-022-01683-w.
Kumar H, Mazumder S, Sharma N, Chakravarti S, Long M, Meurice N
Front Oncol. 2022; 12:842200.
PMID: 35646666
PMC: 9130773.
DOI: 10.3389/fonc.2022.842200.
Serizawa K, Tanaka H, Ueda T, Fukui A, Kakutani H, Taniguchi T
Int J Hematol. 2022; 115(3):336-349.
PMID: 35133572
DOI: 10.1007/s12185-021-03261-0.
Guo W, Wang H, Chen P, Shen X, Zhang B, Liu J
Cancers (Basel). 2021; 13(14).
PMID: 34298738
PMC: 8306148.
DOI: 10.3390/cancers13143523.
Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.
Yang Q, Li K, Li X, Liu J
Int J Med Sci. 2020; 17(14):2063-2076.
PMID: 32922167
PMC: 7484674.
DOI: 10.7150/ijms.48244.
The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
Wang L, Lin N, Li Y
Oncol Rep. 2019; 41(3):1678-1690.
PMID: 30664164
PMC: 6365707.
DOI: 10.3892/or.2019.6968.
Multiple myeloma cancer stem cells.
Gao M, Kong Y, Yang G, Gao L, Shi J
Oncotarget. 2016; 7(23):35466-77.
PMID: 27007154
PMC: 5085244.
DOI: 10.18632/oncotarget.8154.
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?.
Franqui-Machin R, Wendlandt E, Janz S, Zhan F, Tricot G
Oncotarget. 2015; 6(38):40496-506.
PMID: 26415231
PMC: 4747348.
DOI: 10.18632/oncotarget.5800.
MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J, Liu S, He J, Liu X, Qu Y, Yan W
Oncotarget. 2015; 6(17):14993-5007.
PMID: 25915427
PMC: 4558131.
DOI: 10.18632/oncotarget.3802.
Identify multiple myeloma stem cells: Utopia?.
Saltarella I, Lamanuzzi A, Reale A, Vacca A, Ria R
World J Stem Cells. 2015; 7(1):84-95.
PMID: 25621108
PMC: 4300939.
DOI: 10.4252/wjsc.v7.i1.84.
Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors.
Ikegame A, Ozaki S, Tsuji D, Harada T, Fujii S, Nakamura S
Leukemia. 2012; 26(9):2124-34.
PMID: 22430632
DOI: 10.1038/leu.2012.78.
Factors influencing the abundance of the side population in a human myeloma cell line.
Mo S, Li J, Loh Y, Brown R, Smith A, Chen Y
Bone Marrow Res. 2011; 2011:524845.
PMID: 22046565
PMC: 3196862.
DOI: 10.1155/2011/524845.
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y
Haematologica. 2011; 96(10):1512-20.
PMID: 21606160
PMC: 3186313.
DOI: 10.3324/haematol.2010.036814.
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley J
Blood. 2011; 117(17):4409-19.
PMID: 21321360
PMC: 3099565.
DOI: 10.1182/blood-2010-02-267344.
